Clinic CJC-1295

RECORD · 07 / CITATION REGISTER

CJC-1295 references and citations

Every source cited across this console, with DOIs, PubMed IDs, and the trial-registry record — the audit trail behind each figure.

Read the researchBack to the start

The CJC-1295 reference register

These are the CJC-1295 references cited across this site — the peer-reviewed studies, reviews, and registry records behind every quantitative claim. The early human pharmacokinetic work (Teichman 2006; Ionescu/Frohman 2006) anchors the GH and IGF-1 figures and the 5.8-8.1 day DAC half-life [1][3]; the rat bioconjugate study (Jette 2005) establishes the albumin-conjugation mechanism [2]; and the ClinicalTrials.gov record documents the discontinued Phase 2 program (NCT00267527) [7].

Each entry below lists the full citation with its DOI, PubMed ID, or trial-registry identifier so any claim on this site can be traced to source. The full list follows.

  1. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. ↗
  2. Jette L, Leger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. ↗
  3. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797. ↗
  4. Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294. ↗
  5. Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. 2009;19(6):471-477. ↗
  6. Henninge J, Pepaj M, Hullstein I, Hemmersbach P. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Test Anal. 2010;2(11-12):647-650. ↗
  7. ConjuChem Inc. A study to evaluate CJC-1295 in HIV patients with visceral obesity. ClinicalTrials.gov, NCT00267527. 2006. ↗
  8. Growth hormone secretagogue treatment in hypogonadal men raises serum insulin-like growth factor-1 levels. Am J Mens Health. 2017. ↗
  9. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity. J Clin Endocrinol Metab. 2011. ↗
  10. Differential pulsatile secretagogue control of GH secretion in healthy men. Am J Physiol Regul Integr Comp Physiol. 2013. ↗
  11. Granata R, Leone S, Zhang X, Gesmundo I, et al. Growth hormone-releasing hormone and its analogues in health and disease. Nat Rev Endocrinol. 2025. ↗
  12. Granata R, Leone S, Zhang X, Gesmundo I, et al. Growth hormone-releasing hormone and its analogues in health and disease (review of GHRH-analog and GHRP synergy). Nat Rev Endocrinol. 2025. ↗
  13. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers / swine. Pharm Res. 1999. ↗
  14. The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation. Growth Horm IGF Res. 2001. ↗
  15. Modified GRF (1-29) - chemical and pharmacological description. Encyclopedic reference. 2024. ↗